COHANCE - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.6
| Stock Code | COHANCE | Market Cap | 17,360 Cr. | Current Price | 453 ₹ | High / Low | 1,180 ₹ |
| Stock P/E | 51.3 | Book Value | 115 ₹ | Dividend Yield | 0.00 % | ROCE | 16.0 % |
| ROE | 12.5 % | Face Value | 1.00 ₹ | DMA 50 | 374 ₹ | DMA 200 | 574 ₹ |
| Chg in FII Hold | -0.42 % | Chg in DII Hold | 0.22 % | PAT Qtr | 50.8 Cr. | PAT Prev Qtr | 94.3 Cr. |
| RSI | 65.2 | MACD | 38.8 | Volume | 16,35,165 | Avg Vol 1Wk | 60,72,202 |
| Low price | 267 ₹ | High price | 1,180 ₹ | PEG Ratio | -2.49 | Debt to equity | 0.05 |
| 52w Index | 20.4 % | Qtr Profit Var | -67.0 % | EPS | 9.90 ₹ | Industry PE | 30.9 |
📊 COHANCE trades at a high P/E of 51.3 compared to the industry average of 30.9, suggesting premium valuation. ROCE (16.0%) and ROE (12.5%) are moderate, reflecting average efficiency. The PEG ratio is negative (-2.49), indicating weak growth prospects relative to valuation. EPS of ₹9.90 is modest, and quarterly PAT dropped sharply (₹50.8 Cr vs ₹94.3 Cr), raising concerns about earnings consistency. Dividend yield is 0.00%, offering no income support. Debt-to-equity of 0.05 is low, which is positive for financial stability.
💡 Ideal Entry Price Zone: ₹360 – ₹380, close to DMA 50 (₹374) and well below DMA 200 (₹574), offering a margin of safety.
📈 Exit Strategy / Holding Period: For existing holders, a short- to medium-term horizon (1–3 years) is advisable given weak ROE, ROCE, and overvaluation. Consider partial profit booking near ₹1,100–₹1,150 resistance. Long-term investors should be cautious, monitoring earnings consistency and institutional activity before holding further.
✅ Positive
- Debt-to-equity ratio of 0.05 indicates low leverage.
- ROCE of 16.0% and ROE of 12.5% show moderate efficiency.
- EPS of ₹9.90 provides earnings visibility.
- FII holdings decreased only slightly (-0.42%), showing limited foreign exit.
⚠️ Limitation
- P/E of 51.3 is significantly higher than industry average (30.9).
- Negative PEG ratio (-2.49) suggests poor growth prospects.
- Dividend yield of 0.00% offers no income support.
- Quarterly PAT dropped sharply (₹50.8 Cr vs ₹94.3 Cr).
📉 Company Negative News
- Quarterly profit variation (-67.0%) highlights earnings volatility.
- FII holdings decreased (-0.42%), showing reduced foreign investor confidence.
📈 Company Positive News
- DII holdings increased (+0.22%), reflecting domestic institutional support.
- Debt levels remain low, ensuring financial stability.
🏦 Industry
- Pharmaceutical and specialty chemicals sector benefits from global demand but faces pricing pressures.
- Industry P/E of 30.9 positions COHANCE at a premium valuation.
🔎 Conclusion
COHANCE is currently overvalued with weak efficiency metrics and declining profits, making it a risky candidate for long-term investment. Entry around ₹360–₹380 provides margin of safety, but investors should be cautious. Existing holders should consider profit booking near resistance zones, while monitoring institutional activity and earnings trends before committing to extended holding periods.